No significant reductions in the risk of disease progression with G-CHOP relative to R-CHOP were observed for patients with GCB, ABC, or unclassified DLBCL, although a trend towards benefit with G-CHOP compared to R-CHOP was apparent for the GCB subgroup (stratified HR, GCB 0.80, 95% CI 0.58–1.12; ABC 0.91, 95% CI 0.61–1.36; and unclassified 1.10, 95% CI 0.65–1.88; Fig. 3 and Supplementary Fig 1). Here, DDIT3 is linked to diffuse large B-cell lymphoma.